Search Results - PHARMACOTHERAPY OF THE CARDIOVASCULAR AND RESPIRATORY SYSTEMS

  • Showing 1 - 16 results of 16
Refine Results
  1. 1

    The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease by Marcin Wełnicki, Artur Mamcarz, Ernest Kuchar, Przemysław Mitkowski, Jerzy Jaroszewicz, Krzysztof Tomasiewicz, Mariusz Gąsior, Przemysław Leszek, Karol Adam Kamiński, Jacek Wysocki

    Published in Vaccines (2025-05-01)
    “…The COVID-19 pandemic posed a huge challenge to global health systems. In addition to searching for effective methods of treating and preventing infection with a new pathogen, we could once again observe that severe respiratory infection and its complications can be become a challenging problem for cardiac patients. …”
    Get full text
    Article
  2. 2

    Efficacy of liposomal dosage forms and hyperosmolar salines in experimental pharmacotherapy of acute lung injury by Oleg A. Kulikov, Valentin P. Ageev, Elena E. Marochkina, Irina S. Dolgacheva, Olga V. Minayeva, Vera I. Inchina

    Published in Research Results in Pharmacology (2019-06-01)
    “…The efficacy of the therapy was assessed by the survival of animals, functional indicators of the cardiovascular and respiratory systems, and by the lung-body ratio. …”
    Get full text
    Article
  3. 3
  4. 4

    Effects of diaphragmatic breathing exercise on sleeping quality, cortisol, cardiovascular autonomic functions, depression, and fatigue: a randomized-controlled trial in women with... by Ali Mohamed Ali Ismail, Nadia Saad Sayed Ahmed El Gressy, Mona Darwish Hegazy, Omnia Saeed Mahmoud Ahmed, Ahmed Mohamed Abdel-Halim Elfahl

    Published in Rheumatology (2025-04-01)
    “…Introduction The available pharmacotherapies (immunosuppressant therapies) for systemic sclerosis (SSc) are not curative, especially in cases with non-lethal but challenging manifestations or complications of the disease. …”
    Get full text
    Article
  5. 5
  6. 6

    Prevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission by Marović Iva, Udovičić Mario, Rudan Diana, Manola Šime, Samardžić Ivana, Vrca Vesna Bačić, Hadžiabdić Maja Ortner, Marinović Ivana

    Published in Acta Pharmaceutica (2024-12-01)
    “…Specific comorbidities associated with DDIs were arrhythmia, heart failure, diabetes mellitus and disease of the respiratory system. A high prevalence of DDIs of CV medications in all categories of clinical significance was determined. …”
    Get full text
    Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    Monitoring of adverse drug reactions is an important task of pharmacovigilance. Analysis of the regional department of State Expert Center of the Ministry of Health of Ukraine in Z... by O. V. Kraydashenko, I. F. Belenichev, R. V. Stets, Yu. A. Kosogor, L. M. Kaptur

    “…Based on the analysis of spontaneous reports which available in Zaporizhzhia regional department of State Expert Center MoH of Ukraine, drugs that cause unexpected adverse reactions, can be placed in the next order: drugs for the treatment and prevention of infectious diseases, cardiovascular medicines, non-steroidal anti-inflammatory drugs, local anesthetics, hormone drugs, vitamin medicines, medicines that affect the function of the gastrointestinal tract, neurotropic drugs, antihistamine drugs, medicines that affect the function of the respiratory system, plasma substitutes and detoxification solutions.…”
    Get full text
    Article
  12. 12

    Phase I trial of human umbilical cord-derived mesenchymal stem cells for treatment of severe bronchopulmonary dysplasia by Yunqiu Xia, Tingyuan Lang, Yuqin Niu, Xian Wu, Ou Zhou, Jihong Dai, Lei Bao, Ke Yang, Lin Zou, Zhou Fu, Gang Geng

    Published in Genes and Diseases (2023-03-01)
    “…Severe bronchopulmonary dysplasia (BPD) is a chronic lung disorder that primarily affects premature babies with extremely low birth weight and involves in multiple organ system; no effective pharmacotherapy for this disease exists, and mortality remains high. …”
    Get full text
    Article
  13. 13
  14. 14
  15. 15

    The Risk of Arrhythmias in Patients with COVID-19 by Lina Haj Ali, Loredana Suhov, Adrian Apostol, Larissa Dăniluc, Oana Sandu, Carina Bogdan, Viviana Mihaela Ivan

    Published in Biomedicines (2025-06-01)
    “…<b>Background and Objectives:</b> Cardiac arrhythmias during the SARS-CoV-2 infection may occur due to the direct impact of the virus on the respiratory and cardiovascular systems, as well as through the broader effects of systemic inflammation, or a combination of both. …”
    Get full text
    Article
  16. 16

    The Impact of Smoking on General Anesthesia: A Literature Review by Agata Kaptur, Dawid Dziedziński, Dawid Łoś, Aleksandra Nowak, Anita Janus

    Published in Quality in Sport (2024-07-01)
    “…This comprehensive review evaluates the physiological consequences of smoking that challenge anesthetic management, including its effects on respiratory and cardiovascular system. We also analyse the impact smoking has on the metabolism of medications commonly used during anasthesia. …”
    Get full text
    Article

Search Tools: